Tag: Laser ablation

Posted on

MRI‑guided laser interstitial thermal therapy in epilepsy: indications, technique and outcome in an adult population. A single‑center data analysis

Acta Neurochirurgica (2025) 167:39

• MRI-guided Laser Interstitial Thermal Therapy (MRIgLITT) is explored as a treatment for drug-resistant epilepsy (DRE), offering a minimally invasive alternative to open surgery.

• The study conducted a retrospective analysis of 32 MRIgLITT procedures at a single center, focusing on seizure control and cognitive outcomes.

• Patient Demographics: 28 patients with various pathologies, including hippocampal sclerosis (HS), hypothalamic hamartoma (HH), and focal cortical dysplasia (FCD).

• Outcomes: High rates of seizure freedom were observed, particularly in HS and HH patients, with Engel I outcomes achieved in a significant portion.

• Cognitive Changes: 71.44% of patients showed cognitive stability or improvement one year after the procedure.

• Advantages of MRIgLITT: Offers quicker recovery, better cognitive preservation, and is effective for deep or complex epileptic foci.

• Challenges: The relationship between clinical factors and outcomes remains unclear, necessitating further large-scale studies.

• Methodology: The procedure involves precise trajectory planning and real-time MRI monitoring to ensure accurate ablation with minimal impact on surrounding tissues.

Posted on

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation

Neurosurgery 87:E338–E346, 2020

Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality- of-life (QoL) data.

OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms.

METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur.

RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors.

CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabi- lizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real- world registry and comparative to published literature.

Proudly powered by WordPress